Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

C4 Therapeutics (CCCC) Assets Average: 2020-2025

Historic Assets Average for C4 Therapeutics (CCCC) over the last 5 years, with Sep 2025 value amounting to $281.0 million.

  • C4 Therapeutics' Assets Average fell 25.77% to $281.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $281.0 million, marking a year-over-year decrease of 25.77%. This contributed to the annual value of $363.0 million for FY2024, which is 10.06% down from last year.
  • According to the latest figures from Q3 2025, C4 Therapeutics' Assets Average is $281.0 million, which was down 8.77% from $308.0 million recorded in Q2 2025.
  • In the past 5 years, C4 Therapeutics' Assets Average ranged from a high of $518.2 million in Q3 2021 and a low of $281.0 million during Q3 2025.
  • Over the past 3 years, C4 Therapeutics' median Assets Average value was $362.8 million (recorded in 2024), while the average stood at $359.1 million.
  • In the last 5 years, C4 Therapeutics' Assets Average spiked by 61.25% in 2021 and then decreased by 25.78% in 2023.
  • Over the past 5 years, C4 Therapeutics' Assets Average (Quarterly) stood at $507.3 million in 2021, then fell by 12.06% to $446.1 million in 2022, then declined by 20.49% to $354.7 million in 2023, then increased by 2.28% to $362.8 million in 2024, then fell by 25.77% to $281.0 million in 2025.
  • Its last three reported values are $281.0 million in Q3 2025, $308.0 million for Q2 2025, and $334.6 million during Q1 2025.